School of Medicine, University of Notre Dame Australia, Fremantle, Western Australia, Australia.
Murdoch University, Murdoch, Western Australia, Australia.
Pain Pract. 2020 Sep;20(7):737-747. doi: 10.1111/papr.12902. Epub 2020 May 7.
To investigate the preventive effects of a combined antioxidant drug (N-acetylcysteine, vitamin E, and vitamin C [NEC]) on migraine outcomes. Migraine is characterized by increased oxidative stress and neurogenic inflammation in the brain; therefore, antioxidants may have a migraine preventive effect.
Randomized, double-blind, sham-controlled pilot study.
Australian community.
Adults reporting 2 to 8 migraines per month for at least a year.
After a 1-month baseline period, 35 subjects completed 3 months of treatment with NEC (n = 19) or sham (n = 16) capsules. The primary outcome was the difference in mean number of headaches per month between baseline and final month of the trial for NEC and sham groups; secondary outcomes are listed below.
For NEC there was a significant decrease in mean number of headaches by 3.0 per month (P = 0.004) compared with 1.4 for sham (P = 0.073); there was no significant difference in these changes between the 2 groups (P = 0.052). Average monthly headache (P = 0.041) and migraine frequency (P = 0.018) were significantly less for NEC vs. sham. In NEC subjects, there was a significant decrease in average monthly migraine days (-3.1), moderate/severe headache days (-3.2), migraine duration, headache pain scores, and acute headache medication use.
This is the first randomized controlled trial to find that combined antioxidant therapy with NEC reduces headaches and migraines in adult migraineurs. Given the limitations of this pilot study, an adequately powered randomized controlled trial is planned to further investigate antioxidant prophylaxis in migraine.
研究联合抗氧化药物(N-乙酰半胱氨酸、维生素 E 和维生素 C[NEC])对偏头痛结局的预防作用。偏头痛的特征是大脑中氧化应激和神经源性炎症增加;因此,抗氧化剂可能具有预防偏头痛的作用。
随机、双盲、假对照试验研究。
澳大利亚社区。
报告每月有 2 至 8 次偏头痛且至少持续 1 年的成年人。
在 1 个月的基线期后,35 名受试者完成了 3 个月的 NEC(n=19)或假(n=16)胶囊治疗。主要结局是 NEC 和假组从基线到试验最后一个月每月头痛的平均次数差异;次要结局如下。
对于 NEC,每月头痛的平均次数显著减少 3.0 次(P=0.004),而假组为 1.4 次(P=0.073);两组之间这些变化没有显著差异(P=0.052)。NEC 的每月平均头痛(P=0.041)和偏头痛频率(P=0.018)明显低于假组。与假组相比,NEC 组的每月偏头痛天数(-3.1)、中度/重度头痛天数(-3.2)、偏头痛持续时间、头痛疼痛评分和急性头痛药物使用均显著减少。
这是第一项发现联合抗氧化治疗 NEC 可减少成年偏头痛患者头痛和偏头痛的随机对照试验。鉴于本试验研究的局限性,计划进行一项足够大的随机对照试验,以进一步研究偏头痛的抗氧化预防作用。